NCI-2023-05813

A Phase 3, Open-Label, Randomized, Multi-Center Study ofDZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

This Phase 3 study is comparing a new treatment called DZD9008 with standard chemotherapy as the first treatment for patients with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that has a particular genetic change called EGFR exon 20 insertion mutation. DZD9008 targets this specific mutation. The study aims to see if DZD9008 works better and is safer than standard chemotherapy for these patients, with the goal of finding a better treatment option for people with NSCLC who have this specific genetic change.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

EGFR: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05668988

Clinical Trial Site: Columbia

To see all available clinical trials click here.